Your browser doesn't support javascript.
loading
Morbidity and Mortality in Adult Fontan Patients After Heart or Combined Heart-Liver Transplantation.
Lewis, Matthew J; Reardon, Leigh C; Aboulhosn, Jamil; Haeffele, Christiane; Chen, Sharon; Kim, Yuli; Fuller, Stephanie; Forbess, Lisa; Alshawabkeh, Laith; Urey, Marcus A; Book, Wendy M; Rodriguez, Fred; Menachem, Jonathan N; Clark, Daniel E; Valente, Anne Marie; Carazo, Matthew; Egbe, Alexander; Connolly, Heidi M; Krieger, Eric V; Angiulo, Jilian; Cedars, Ari; Ko, Jong; Jacobsen, Roni M; Earing, Michael G; Cramer, Jonathan W; Ermis, Peter; Broda, Christopher; Nugaeva, Natalia; Ross, Heather; Awerbach, Jordan D; Krasuski, Richard A; Rosenbaum, Marlon.
Affiliation
  • Lewis MJ; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA. Electronic address: ml3329@columbia.edu.
  • Reardon LC; Department of Medicine, Division of Cardiology, Ahmason/UCLA Adult Congenital Heart Disease Center, University of California Los Angeles, Los Angeles, California, USA.
  • Aboulhosn J; Department of Medicine, Division of Cardiology, Ahmason/UCLA Adult Congenital Heart Disease Center, University of California Los Angeles, Los Angeles, California, USA.
  • Haeffele C; Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Palo Alto, California, USA.
  • Chen S; Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Palo Alto, California, USA.
  • Kim Y; Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Fuller S; Division of Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Forbess L; Division of Pediatric Cardiology, Department of Pediatrics, Northwestern University, Ann and Robert Lurie Children's Hospital, Chicago, Illinois, USA.
  • Alshawabkeh L; Division of Cardiology, Department of Medicine, University of California, San Diego, California, USA.
  • Urey MA; Division of Cardiology, Department of Medicine, University of California, San Diego, California, USA.
  • Book WM; Division of Cardiology, Department of Medicine, Emory University, Atlanta, Georgia, USA.
  • Rodriguez F; Division of Cardiology, Department of Medicine, Emory University, Atlanta, Georgia, USA.
  • Menachem JN; Division of Cardiology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Clark DE; Division of Cardiology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Valente AM; Department of Cardiology, Boston Children's Hospital, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts, USA.
  • Carazo M; Department of Cardiology, Boston Children's Hospital, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts, USA.
  • Egbe A; Division of Cardiology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Connolly HM; Division of Cardiology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Krieger EV; Division of Cardiology, Department of Medicine University of Washington and Seattle Children's Hospital, Seattle, Washington, USA.
  • Angiulo J; Division of Cardiology, Department of Medicine University of Washington and Seattle Children's Hospital, Seattle, Washington, USA.
  • Cedars A; Division of Cardiology, Department of Medicine, UT Southwestern, Dallas, Texas, USA.
  • Ko J; Division of Cardiology, Department of Medicine, UT Southwestern, Dallas, Texas, USA.
  • Jacobsen RM; Division of Cardiology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Earing MG; Division of Cardiology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Cramer JW; Department of Pediatrics and Internal Medicine, Division of Cardiology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Ermis P; Division of Pediatric Cardiology and Adult Congenital Heart Disease, Department of Pediatrics, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA.
  • Broda C; Division of Pediatric Cardiology and Adult Congenital Heart Disease, Department of Pediatrics, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA.
  • Nugaeva N; Division of Cardiology, Department of Medicine, University Health Network, Toronto, Ontario, Canada.
  • Ross H; Division of Cardiology, Department of Medicine, University Health Network, Toronto, Ontario, Canada.
  • Awerbach JD; Division of Cardiology, Phoenix Children's, Phoenix, AZ, Divisions of Child Health and Internal Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA.
  • Krasuski RA; Division of Cardiology, Department of Medicine, Duke University, Raleigh Durham, North Carolina, USA.
  • Rosenbaum M; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
J Am Coll Cardiol ; 81(22): 2161-2171, 2023 06 06.
Article in En | MEDLINE | ID: mdl-37257951
ABSTRACT

BACKGROUND:

An increasing number of adult Fontan patients require heart transplantation (HT) or combined heart-liver transplant (CHLT); however, data regarding outcomes and optimal referral time remain limited.

OBJECTIVES:

The purpose of this study was to define survivorship post-HT/CHLT and predictors of post-transplant mortality, including timing of referral, in the adult Fontan population.

METHODS:

A retrospective cohort study of adult Fontan patients who underwent HT or CHLT across 15 centers in the United States and Canada was performed. Inclusion criteria included the following 1) Fontan; 2) HT/CHLT referral; and 3) age ≥16 years at the time of referral. Date of "failing" Fontan was defined as the earliest of the following worsening fluid retention, new ascites, refractory arrhythmia, "failing Fontan" diagnosis by treating cardiologist, or admission for heart failure.

RESULTS:

A total of 131 patients underwent transplant, including 40 CHLT, from 1995 to 2021 with a median post-transplant follow-up time of 1.6 years (Q1 0.35 years, Q3 4.3 years). Survival was 79% at 1 year and 66% at 5 years. Survival differed by decade of transplantation and was 87% at 1 year and 76% at 5 years after 2010. Time from Fontan failure to evaluation (HR/year 1.23 [95% CI 1.11-1.36]; P < 0.001) and markers of failure, including NYHA functional class IV (HR 2.29 [95% CI 1.10-5.28]; P = 0.050), lower extremity varicosities (HR 3.92 [95% CI 1.68-9.14]; P = 0.002), and venovenous collaterals (HR 2.70 [95% CI 1.17-6.20]; P = 0.019), were associated with decreased post-transplant survival at 1 year in a bivariate model that included transplant decade.

CONCLUSIONS:

In our multicenter cohort, post-transplant survival improved over time. Late referral after Fontan failure and markers of failing Fontan physiology, including worse functional status, lower extremity varicosities, and venovenous collaterals, were associated with post-transplant mortality.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Heart Transplantation / Liver Transplantation / Fontan Procedure / Heart Defects, Congenital / Heart Failure Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Humans Language: En Journal: J Am Coll Cardiol Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Heart Transplantation / Liver Transplantation / Fontan Procedure / Heart Defects, Congenital / Heart Failure Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Humans Language: En Journal: J Am Coll Cardiol Year: 2023 Document type: Article
...